Intrinsic value of Core Laboratories - CLB

Previous Close

$105.69

  Intrinsic Value

$15.00

stock screener

  Rating & Target

str. sell

-86%

  Value-price divergence*

-67%

Previous close

$105.69

 
Intrinsic value

$15.00

 
Up/down potential

-86%

 
Rating

str. sell

 
Value-price divergence*

-67%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of CLB stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 4.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -25.44
  2.60
  2.84
  3.06
  3.25
  3.43
  3.58
  3.72
  3.85
  3.97
  4.07
  4.16
  4.25
  4.32
  4.39
  4.45
  4.51
  4.56
  4.60
  4.64
  4.68
  4.71
  4.74
  4.76
  4.79
  4.81
  4.83
  4.84
  4.86
  4.87
  4.89
Revenue, $m
  595
  610
  628
  647
  668
  691
  716
  742
  771
  801
  834
  869
  906
  945
  986
  1,030
  1,077
  1,126
  1,178
  1,232
  1,290
  1,350
  1,414
  1,482
  1,553
  1,627
  1,706
  1,789
  1,876
  1,967
  2,063
Variable operating expenses, $m
 
  382
  392
  404
  418
  432
  447
  464
  482
  501
  521
  543
  566
  591
  616
  644
  673
  704
  736
  770
  806
  844
  884
  926
  970
  1,017
  1,066
  1,118
  1,172
  1,229
  1,289
Fixed operating expenses, $m
 
  144
  147
  151
  155
  158
  162
  166
  171
  175
  179
  184
  188
  193
  198
  203
  208
  213
  218
  224
  229
  235
  241
  247
  253
  260
  266
  273
  280
  286
  294
Total operating expenses, $m
  509
  526
  539
  555
  573
  590
  609
  630
  653
  676
  700
  727
  754
  784
  814
  847
  881
  917
  954
  994
  1,035
  1,079
  1,125
  1,173
  1,223
  1,277
  1,332
  1,391
  1,452
  1,515
  1,583
Operating income, $m
  86
  85
  88
  92
  96
  101
  106
  112
  119
  126
  134
  142
  151
  161
  172
  184
  196
  209
  223
  238
  254
  271
  289
  309
  329
  351
  374
  398
  424
  451
  480
EBITDA, $m
  113
  113
  117
  121
  126
  132
  139
  146
  154
  162
  172
  182
  193
  204
  217
  230
  245
  260
  277
  294
  313
  333
  354
  376
  400
  425
  451
  479
  509
  541
  574
Interest expense (income), $m
  11
  8
  8
  8
  9
  9
  10
  11
  11
  12
  13
  13
  14
  15
  16
  17
  18
  20
  21
  22
  23
  25
  26
  28
  30
  31
  33
  35
  37
  39
  42
Earnings before tax, $m
  75
  78
  80
  83
  87
  91
  96
  101
  107
  114
  121
  129
  137
  146
  156
  166
  178
  190
  202
  216
  231
  246
  263
  281
  300
  319
  341
  363
  387
  412
  438
Tax expense, $m
  11
  21
  22
  23
  24
  25
  26
  27
  29
  31
  33
  35
  37
  39
  42
  45
  48
  51
  55
  58
  62
  67
  71
  76
  81
  86
  92
  98
  104
  111
  118
Net income, $m
  64
  57
  59
  61
  64
  67
  70
  74
  78
  83
  88
  94
  100
  107
  114
  121
  130
  138
  148
  158
  169
  180
  192
  205
  219
  233
  249
  265
  282
  301
  320

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  15
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  573
  573
  589
  607
  627
  648
  671
  696
  723
  752
  782
  815
  850
  886
  925
  966
  1,010
  1,056
  1,105
  1,156
  1,210
  1,267
  1,327
  1,390
  1,457
  1,527
  1,600
  1,678
  1,759
  1,845
  1,935
Adjusted assets (=assets-cash), $m
  558
  573
  589
  607
  627
  648
  671
  696
  723
  752
  782
  815
  850
  886
  925
  966
  1,010
  1,056
  1,105
  1,156
  1,210
  1,267
  1,327
  1,390
  1,457
  1,527
  1,600
  1,678
  1,759
  1,845
  1,935
Revenue / Adjusted assets
  1.066
  1.065
  1.066
  1.066
  1.065
  1.066
  1.067
  1.066
  1.066
  1.065
  1.066
  1.066
  1.066
  1.067
  1.066
  1.066
  1.066
  1.066
  1.066
  1.066
  1.066
  1.066
  1.066
  1.066
  1.066
  1.065
  1.066
  1.066
  1.067
  1.066
  1.066
Average production assets, $m
  325
  333
  343
  353
  365
  377
  391
  405
  421
  438
  455
  474
  495
  516
  539
  563
  588
  615
  643
  673
  704
  737
  772
  809
  848
  889
  931
  977
  1,024
  1,074
  1,126
Working capital, $m
  82
  69
  71
  73
  75
  78
  81
  84
  87
  91
  94
  98
  102
  107
  111
  116
  122
  127
  133
  139
  146
  153
  160
  167
  175
  184
  193
  202
  212
  222
  233
Total debt, $m
  216
  227
  239
  253
  268
  284
  302
  320
  341
  362
  386
  410
  436
  464
  494
  525
  558
  592
  629
  668
  709
  752
  797
  845
  895
  948
  1,004
  1,063
  1,124
  1,189
  1,257
Total liabilities, $m
  422
  433
  445
  459
  474
  490
  508
  526
  547
  568
  592
  616
  642
  670
  700
  731
  764
  798
  835
  874
  915
  958
  1,003
  1,051
  1,101
  1,154
  1,210
  1,269
  1,330
  1,395
  1,463
Total equity, $m
  151
  140
  144
  148
  153
  158
  164
  170
  176
  183
  191
  199
  207
  216
  226
  236
  246
  258
  270
  282
  295
  309
  324
  339
  355
  373
  390
  409
  429
  450
  472
Total liabilities and equity, $m
  573
  573
  589
  607
  627
  648
  672
  696
  723
  751
  783
  815
  849
  886
  926
  967
  1,010
  1,056
  1,105
  1,156
  1,210
  1,267
  1,327
  1,390
  1,456
  1,527
  1,600
  1,678
  1,759
  1,845
  1,935
Debt-to-equity ratio
  1.430
  1.620
  1.660
  1.710
  1.750
  1.800
  1.840
  1.890
  1.930
  1.980
  2.020
  2.060
  2.100
  2.150
  2.190
  2.220
  2.260
  2.300
  2.330
  2.370
  2.400
  2.430
  2.460
  2.490
  2.520
  2.550
  2.570
  2.600
  2.620
  2.640
  2.660
Adjusted equity ratio
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244
  0.244

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  64
  57
  59
  61
  64
  67
  70
  74
  78
  83
  88
  94
  100
  107
  114
  121
  130
  138
  148
  158
  169
  180
  192
  205
  219
  233
  249
  265
  282
  301
  320
Depreciation, amort., depletion, $m
  27
  28
  29
  29
  30
  31
  33
  34
  35
  36
  38
  40
  41
  43
  45
  47
  49
  51
  54
  56
  59
  61
  64
  67
  71
  74
  78
  81
  85
  90
  94
Funds from operations, $m
  167
  85
  87
  90
  94
  98
  103
  108
  113
  120
  126
  133
  141
  150
  159
  168
  179
  190
  201
  214
  227
  241
  256
  272
  289
  307
  326
  346
  368
  390
  414
Change in working capital, $m
  35
  2
  2
  2
  2
  3
  3
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
  10
  10
  11
Cash from operations, $m
  132
  83
  85
  88
  92
  96
  100
  105
  110
  116
  123
  130
  137
  145
  154
  163
  173
  184
  196
  208
  221
  235
  249
  265
  281
  299
  317
  337
  358
  380
  403
Maintenance CAPEX, $m
  0
  -27
  -28
  -29
  -29
  -30
  -31
  -33
  -34
  -35
  -36
  -38
  -40
  -41
  -43
  -45
  -47
  -49
  -51
  -54
  -56
  -59
  -61
  -64
  -67
  -71
  -74
  -78
  -81
  -85
  -90
New CAPEX, $m
  -12
  -8
  -9
  -10
  -11
  -12
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -23
  -24
  -25
  -27
  -28
  -30
  -31
  -33
  -35
  -37
  -39
  -41
  -43
  -45
  -47
  -50
  -52
Cash from investing activities, $m
  -15
  -35
  -37
  -39
  -40
  -42
  -45
  -48
  -50
  -52
  -54
  -57
  -60
  -62
  -66
  -69
  -72
  -76
  -79
  -84
  -87
  -92
  -96
  -101
  -106
  -112
  -117
  -123
  -128
  -135
  -142
Free cash flow, $m
  117
  47
  48
  49
  51
  53
  55
  58
  61
  64
  68
  73
  77
  83
  88
  94
  101
  108
  116
  124
  133
  143
  153
  164
  175
  187
  200
  214
  229
  245
  261
Issuance/(repayment) of debt, $m
  -217
  11
  12
  14
  15
  16
  18
  19
  20
  22
  23
  25
  26
  28
  29
  31
  33
  35
  37
  39
  41
  43
  45
  48
  50
  53
  56
  59
  62
  65
  68
Issuance/(repurchase) of shares, $m
  190
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -30
  11
  12
  14
  15
  16
  18
  19
  20
  22
  23
  25
  26
  28
  29
  31
  33
  35
  37
  39
  41
  43
  45
  48
  50
  53
  56
  59
  62
  65
  68
Total cash flow (excl. dividends), $m
  87
  58
  60
  63
  66
  69
  73
  77
  81
  86
  91
  97
  104
  110
  118
  126
  134
  143
  153
  163
  174
  186
  198
  211
  225
  240
  256
  273
  291
  309
  329
Retained Cash Flow (-), $m
  -180
  -4
  -4
  -4
  -5
  -5
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -9
  -9
  -10
  -11
  -11
  -12
  -13
  -13
  -14
  -15
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
Prev. year cash balance distribution, $m
 
  15
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  70
  56
  58
  61
  64
  67
  70
  75
  79
  84
  89
  95
  101
  108
  116
  123
  132
  141
  151
  161
  172
  184
  196
  209
  223
  238
  254
  271
  288
  307
Discount rate, %
 
  6.30
  6.62
  6.95
  7.29
  7.66
  8.04
  8.44
  8.86
  9.31
  9.77
  10.26
  10.78
  11.31
  11.88
  12.47
  13.10
  13.75
  14.44
  15.16
  15.92
  16.72
  17.55
  18.43
  19.35
  20.32
  21.33
  22.40
  23.52
  24.70
  25.93
PV of cash for distribution, $m
 
  66
  50
  48
  46
  44
  42
  40
  38
  35
  33
  30
  28
  25
  22
  20
  17
  15
  12
  10
  8
  7
  5
  4
  3
  2
  2
  1
  1
  0
  0
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Core Laboratories N.V. provides reservoir description, production enhancement, and reservoir management services to the oil and gas industry in the United States, Canada, and internationally. It operates through three segments: Reservoir Description, Production Enhancement, and Reservoir Management. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples. This segment offers analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry. The Production Enhancement segment includes services and products relating to reservoir well completions, perforations, stimulations, and production. This segment offers integrated services to evaluate the effectiveness of well completions and to develop solutions to enhance the effectiveness of enhanced oil recovery projects. The Reservoir Management segment combines and integrates information from reservoir description, as well as provides production enhancement services to increase the production and improve recovery of oil and gas from its clientÂ’s reservoirs. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories N.V. was founded in 1936 and is based in Amsterdam, the Netherlands.

FINANCIAL RATIOS  of  Core Laboratories (CLB)

Valuation Ratios
P/E Ratio 72.9
Price to Sales 7.8
Price to Book 30.9
Price to Tangible Book
Price to Cash Flow 35.4
Price to Free Cash Flow 38.9
Growth Rates
Sales Growth Rate -25.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -50%
Cap. Spend. - 3 Yr. Gr. Rate -21%
Financial Strength
Quick Ratio NaN
Current Ratio 0.1
LT Debt to Equity 143%
Total Debt to Equity 143%
Interest Coverage 8
Management Effectiveness
Return On Assets 12.3%
Ret/ On Assets - 3 Yr. Avg. 23.7%
Return On Total Capital 16.6%
Ret/ On T. Cap. - 3 Yr. Avg. 34.3%
Return On Equity 104.9%
Return On Equity - 3 Yr. Avg. 233.2%
Asset Turnover 1
Profitability Ratios
Gross Margin 25.5%
Gross Margin - 3 Yr. Avg. 32.5%
EBITDA Margin 19%
EBITDA Margin - 3 Yr. Avg. 25.6%
Operating Margin 14.5%
Oper. Margin - 3 Yr. Avg. 22.2%
Pre-Tax Margin 12.6%
Pre-Tax Margin - 3 Yr. Avg. 20.7%
Net Profit Margin 10.8%
Net Profit Margin - 3 Yr. Avg. 16.3%
Effective Tax Rate 14.7%
Eff/ Tax Rate - 3 Yr. Avg. 20.1%
Payout Ratio 148.4%

CLB stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CLB stock intrinsic value calculation we used $595 million for the last fiscal year's total revenue generated by Core Laboratories. The default revenue input number comes from 2016 income statement of Core Laboratories. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CLB stock valuation model: a) initial revenue growth rate of 2.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.3%, whose default value for CLB is calculated based on our internal credit rating of Core Laboratories, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Core Laboratories.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CLB stock the variable cost ratio is equal to 62.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $140 million in the base year in the intrinsic value calculation for CLB stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Core Laboratories.

Corporate tax rate of 27% is the nominal tax rate for Core Laboratories. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CLB stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CLB are equal to 54.6%.

Life of production assets of 12 years is the average useful life of capital assets used in Core Laboratories operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CLB is equal to 11.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $151 million for Core Laboratories - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 43.709 million for Core Laboratories is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Core Laboratories at the current share price and the inputted number of shares is $4.6 billion.

RELATED COMPANIES Price Int.Val. Rating
SLB Schlumberger 66.53 34.01  sell
IO ION Geophysica 3.35 199.65  str.buy

COMPANY NEWS

▶ What Analysts Forecast for NOV ahead of 2Q17 Earnings   [Jul-17-17 09:06AM  Market Realist]
▶ Shorting HAL: Short Interest in Halliburton as of July 10   [Jul-13-17 10:36AM  Market Realist]
▶ Core Laboratories N.V.: The Bear Case From a Bull   [Jul-10-17 11:33AM  Motley Fool]
▶ 3 Top Energy Stocks to Buy Now   [Jun-24-17 02:04PM  Motley Fool]
▶ Analysts Recommendations for Halliburton   [Jun-16-17 07:36AM  Market Realist]
▶ Halliburtons Valuation Compared to Its Peers   [Jun-14-17 02:36PM  Market Realist]
▶ Whats NOVs Correlation with Crude Oil in June 2017?   [Jun-13-17 07:36AM  Market Realist]
▶ What Was Halliburtons Correlation with Crude Oil on June 2?   [Jun-05-17 02:35PM  Market Realist]
▶ 2 Reasons Oil Could Go Back to $100   [May-26-17 02:15PM  Motley Fool]
▶ What Would Get Oil Back to $100 a Barrel?   [May-23-17 04:45PM  Motley Fool]
▶ Wall Streets Forecast for National Oilwell Varco   [May-17-17 07:36AM  Market Realist]
▶ Whats Basic Energy Services Valuation?   [07:36AM  Market Realist]
▶ ETFs with exposure to Core Laboratories NV : May 9, 2017   [May-09-17 04:25PM  Capital Cube]
▶ Sohn Investment Conference 2017: Live Blog   [09:37AM  Investopedia]
▶ [$$] Hedge Funds Pitch Teletubbies, Tesla at Sohn   [May-08-17 11:53PM  The Wall Street Journal]
▶ How Schlumberger Correlates with Crude Oil   [01:35PM  Market Realist]
▶ Inside Halliburtons Correlation with Crude Oil on April 28   [May-02-17 07:40AM  Market Realist]
▶ Want to Invest in Fracking? Look at These Companies   [Apr-28-17 02:15PM  Motley Fool]
▶ Whats NOVs Correlation with Crude Oil on April 21?   [Apr-24-17 01:35PM  Market Realist]
▶ Core Laboratories N.V. Results Continue to Rebound   [Apr-20-17 09:00AM  Motley Fool]
▶ Core Laboratories tops Street 1Q forecasts   [Apr-19-17 04:58PM  Associated Press]
▶ Core Lab Announces Q2 2017 Quarterly Dividend   [Apr-18-17 04:49PM  PR Newswire]
▶ David Rolfe Comments on Core Labs   [Apr-14-17 05:00PM  GuruFocus.com]
▶ The 3 Best-Kept Secret Stocks of the Oil & Gas Sector   [Apr-12-17 08:34AM  Motley Fool]
▶ 3 Beaten-Down Stocks Ready to Bounce Back   [Apr-07-17 08:47AM  Motley Fool]
▶ 3 Little-Known Energy Companies to Put on Your Radar   [Mar-31-17 02:42PM  Motley Fool]
▶ 3 Energy Stocks Wall Street Hates but You Should Love   [Mar-22-17 11:04AM  Motley Fool]
▶ 5 Reasons to Buy Core Laboratories N.V. Now   [Mar-21-17 12:00PM  Motley Fool]
▶ 5 Reasons to Buy Core Laboratories N.V. Now   [12:00PM  at Motley Fool]
▶ Whats Weatherfords Correlation with Crude Oil?   [Mar-20-17 01:35PM  Market Realist]
▶ 5 Great Oil Stocks To Grow Your Portfolio   [Mar-07-17 11:52AM  Insider Monkey]
▶ 5 Great Oil Stocks To Grow Your Portfolio   [11:52AM  at Insider Monkey]
▶ These 2 Hated Dividend Stocks Are Buys   [Feb-28-17 11:01AM  at Motley Fool]
▶ Why Investors Are Paying a Premium for Core Laboratories   [Feb-25-17 01:49PM  at Motley Fool]
Stock chart of CLB Financial statements of CLB Annual reports of CLB
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.